Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Shield Across America ...
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding ...
Shield is the first and only blood test to receive FDA approval as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. In the analysis looking at the initial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results